Sartorius AG

Sartorius AG

Sartorius AG was founded in 1870 in Göttingen, Germany, by August Sartorius and Richard Spindler. The company initially focused on precision balances and laboratory equipment. Today it is a publicly-listed entity on the Frankfurt Stock Exchange and its American Depositary Receipt trades OTC in the US. The underlying wealth originates from the founding families and subsequent public shareholders — the Sartorius family retains a controlling stake through preference shares. The firm's strategy centers on the life sciences and biopharmaceutical end markets. Sartorius operates through two segments: Bioprocess Solutions, which provides single-use technologies and fermentation equipment for vaccine and biologic production, and Lab Products & Services, which sells lab instruments and consumables into academic and pharma R&D. Geographic revenue is split roughly 25% Americas, 30% EMEA, 45% Asia/Pacific (per annual filings, 2024). Confirmed client engagements include major global biopharma companies such as Roche, Novartis, and Pfizer. Sartorius employs approximately 16,000 people and reports annual revenue of roughly €3.4 billion (per FY2024 figures). It maintains production and R&D sites in Germany, France, the US, China, and Singapore. The Sartorius family holds majority voting power through non-listed preference shares, a governance structure established at IPO. No adjacent philanthropic or operating vehicles are separately disclosed in public filings. Sartorius's structural differentiator lies in its controlling-family governance: the Sartorius family retains roughly 55% voting control through preference shares, a design intended to protect long-term R&D and capital expenditure cycles from quarterly earnings pressure. The company also maintains a dual share class structure that separates economic ownership from voting control.